Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Aptamer-mediated delivery of chemotherapy to pancreatic cancer cells.

Ray P, Cheek MA, Sharaf ML, Li N, Ellington AD, Sullenger BA, Shaw BR, White RR.

Nucleic Acid Ther. 2012 Oct;22(5):295-305. doi: 10.1089/nat.2012.0353.

2.

ALPPL2 Aptamer-Mediated Targeted Delivery of 5-Fluoro-2'-Deoxyuridine to Pancreatic Cancer.

Dua P, S S, Kim S, Lee DK.

Nucleic Acid Ther. 2015 Aug;25(4):180-7. doi: 10.1089/nat.2014.0516. Epub 2015 Apr 28.

PMID:
25919296
3.

KML001 enhances anticancer activity of gemcitabine against pancreatic cancer cells.

Yang MH, Lee KT, Yang S, Lee JK, Lee KH, Rhee JC.

Anticancer Res. 2015 Jan;35(1):183-9.

PMID:
25550550
4.

Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer.

Bianco C, Giovannetti E, Ciardiello F, Mey V, Nannizzi S, Tortora G, Troiani T, Pasqualetti F, Eckhardt G, de Liguoro M, Ricciardi S, Del Tacca M, Raben D, Cionini L, Danesi R.

Clin Cancer Res. 2006 Dec 1;12(23):7099-107.

5.

HMGA-targeted phosphorothioate DNA aptamers increase sensitivity to gemcitabine chemotherapy in human pancreatic cancer cell lines.

Watanabe M, Sheriff S, Lewis KB, Tinch SL, Cho J, Balasubramaniam A, Kennedy MA.

Cancer Lett. 2012 Feb 1;315(1):18-27. doi: 10.1016/j.canlet.2011.10.005. Epub 2011 Oct 10.

6.

Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer.

Venkatasubbarao K, Peterson L, Zhao S, Hill P, Cao L, Zhou Q, Nawrocki ST, Freeman JW.

Mol Cancer. 2013 Sep 11;12(1):104. doi: 10.1186/1476-4598-12-104.

7.

Inhibition of cell proliferation by an anti-EGFR aptamer.

Li N, Nguyen HH, Byrom M, Ellington AD.

PLoS One. 2011;6(6):e20299. doi: 10.1371/journal.pone.0020299. Epub 2011 Jun 8.

8.

Dual ErbB1 and ErbB2 receptor tyrosine kinase inhibition exerts synergistic effect with conventional chemotherapy in pancreatic cancer.

Singla S, Pippin JA, Drebin JA.

Oncol Rep. 2012 Dec;28(6):2211-6. doi: 10.3892/or.2012.2053. Epub 2012 Sep 24.

PMID:
23007710
9.
10.

Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas.

Pignochino Y, Sarotto I, Peraldo-Neia C, Penachioni JY, Cavalloni G, Migliardi G, Casorzo L, Chiorino G, Risio M, Bardelli A, Aglietta M, Leone F.

BMC Cancer. 2010 Nov 18;10:631. doi: 10.1186/1471-2407-10-631.

11.

Synergy of gemcitabine and lidamycin associated with NF-kappaB downregulation in pancreatic carcinoma cells.

Chen J, Wu SY, Ou-Yang ZG, Zhen YS.

Acta Pharmacol Sin. 2008 May;29(5):614-9. doi: 10.1111/j.1745-7254.2008.00774.x.

12.
13.

Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer.

Azorsa DO, Gonzales IM, Basu GD, Choudhary A, Arora S, Bisanz KM, Kiefer JA, Henderson MC, Trent JM, Von Hoff DD, Mousses S.

J Transl Med. 2009 Jun 11;7:43. doi: 10.1186/1479-5876-7-43.

14.

Inhibition of oncogenic Pim-3 kinase modulates transformed growth and chemosensitizes pancreatic cancer cells to gemcitabine.

Xu D, Cobb MG, Gavilano L, Witherspoon SM, Williams D, White CD, Taverna P, Bednarski BK, Kim HJ, Baldwin AS, Baines AT.

Cancer Biol Ther. 2013 Jun;14(6):492-501. doi: 10.4161/cbt.24343.

15.

Gene therapy based on gemcitabine chemosensitization suppresses pancreatic tumor growth.

Vernejoul F, Ghénassia L, Souque A, Lulka H, Drocourt D, Cordelier P, Pradayrol L, Pyronnet S, Buscail L, Tiraby G.

Mol Ther. 2006 Dec;14(6):758-67. Epub 2006 Sep 25.

PMID:
17000136
16.

Preparation of pH-sensitive, long-circulating and EGFR-targeted immunoliposomes.

Kim MJ, Lee HJ, Lee IA, Kim IY, Lim SK, Cho HA, Kim JS.

Arch Pharm Res. 2008 Apr;31(4):539-46. doi: 10.1007/s12272-001-1190-9. Epub 2008 May 1.

PMID:
18449514
17.

Just getting into cells is not enough: mechanisms underlying 4-(N)-stearoyl gemcitabine solid lipid nanoparticle's ability to overcome gemcitabine resistance caused by RRM1 overexpression.

Wonganan P, Lansakara-P DS, Zhu S, Holzer M, Sandoval MA, Warthaka M, Cui Z.

J Control Release. 2013 Jul 10;169(1-2):17-27. doi: 10.1016/j.jconrel.2013.03.033. Epub 2013 Apr 6.

18.

Combined blockade of Src kinase and epidermal growth factor receptor with gemcitabine overcomes STAT3-mediated resistance of inhibition of pancreatic tumor growth.

Nagaraj NS, Washington MK, Merchant NB.

Clin Cancer Res. 2011 Feb 1;17(3):483-93. doi: 10.1158/1078-0432.CCR-10-1670. Epub 2011 Jan 25.

19.

Target-specific delivery of doxorubicin to retinoblastoma using epithelial cell adhesion molecule aptamer.

Subramanian N, Raghunathan V, Kanwar JR, Kanwar RK, Elchuri SV, Khetan V, Krishnakumar S.

Mol Vis. 2012;18:2783-95. Epub 2012 Nov 22.

20.

Temperature-sensitive magnetic drug carriers for concurrent gemcitabine chemohyperthermia.

Kim DH, Guo Y, Zhang Z, Procissi D, Nicolai J, Omary RA, Larson AC.

Adv Healthc Mater. 2014 May;3(5):714-24. doi: 10.1002/adhm.201300209. Epub 2013 Oct 21.

Items per page

Supplemental Content

Write to the Help Desk